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Background
Threat of haemolytic anaemia in individuals with a defi-
ciency in glucose-6-phosphate dehydrogenase (G6PD)
enzyme activity prevents widespread use of primaquine, a
vital drug for malaria elimination. Significant genetic varia-
tion underpins this human enzyme disorder, reflected as a
spectrum of clinical severity following exposure to oxida-
tive agents such as primaquine. Across malaria endemic
countries (MECs), the prevalence and genetic basis of this
predisposing condition vary greatly. An understanding of
the relative risks presented by G6PD deficiency, in terms
of prevalence and severity, is necessary to rationally deter-
mine primaquine drug policy.
Materials and methods
We assembled a geo-referenced database documenting
the spatial distribution of G6PD variants. A suite of maps
were developed to illustrate this current state of under-
standing, including occurrence maps of the commonly
reported variants and, where population samples were
locally representative, maps detailing the relative preva-
lence of co-occurring variants. Countries were stratified
according to the relative severity of the variants reported.
These categorisations were combined with ranks of the
overall frequency of deficiency in each country, resulting
in an overall index of G6PD deficiency associated risk. A
parallel index of uncertainty in the index was also
developed.
Results
The variant maps presented here make apparent the
important contrasts between the spatial variants of
G6PD deficiency between populations. As well as diver-
sity among the variants identified within populations,
there is great heterogeneity between the dominant var-
iants identified between different populations. The Med-
iterranean variant was found to be the predominant
variant in MECs across west Asia, where prevalence of
deficiency was also high; these countries therefore
ranked highest on the risk index. Across the Asian con-
tinent, risk from G6PD remained high due to the sever-
ity of reported variants and the disorder being relatively
common. The low severity of variants reported from
sub-Saharan African countries resulted in lower risk
categorisation relative to Asia, though uncertainty in the
data from this continent was high.
Conclusions
Developing an evidence-base to support primaquine drug
policy is essential. We present a cartographic suite and a
framework for stratifying risk for regional comparisons.
The risk index proposed here required several assump-
tions to overcome significant knowledge gaps. A deeper
understanding of the common variants’ primaquine sensi-
tivity phenotypes is essential to maximise safe and effective
use of primaquine.
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